Drugs / CSTI-500
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05504395 | Nov 2022 → Feb 2023 | Prader-Willi syndrome | ConSynance Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07348601 | May 2026 → Jun 2027 expected | Prader-Willi syndrome | ConSynance Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSTI-500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05504395 ↗ |
| Route | Oral | “a 10 mg single oral dose of CSTI-500” NCT05504395 ↗ |